Krystal Biotech Inc

KRYS

Company Profile

  • Business description

    Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.

  • Contact

    2100 Wharton Street
    Suite 701
    PittsburghPA15203
    USA

    T: +1 412 586-5830

    E: [email protected]

    https://www.krystalbio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    295

Stocks News & Analysis

stocks

Strong guidance from undervalued ASX share

Shares surged after the announcement of first half fiscal 2026 guidance.
stocks

TSMC earnings: Refining guidance and expansion plans amid strong AI demand

We maintain our fair value estimate for TSMC stock.
stocks

Unconventional wisdom: A top performing ‘AI share’ accidently ended up in my portfolio

Trying to make sense of a share caught up in irrational exuberance.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,168.7033.000.36%
CAC 408,296.9534.250.41%
DAX 4024,309.90155.430.64%
Dow JONES (US)48,578.72115.000.24%
FTSE 10010,584.045.95-0.06%
HKSE26,160.33233.93-0.89%
NASDAQ24,102.7086.690.36%
Nikkei 22558,475.901,042.44-1.75%
NZX 50 Index12,905.67160.39-1.23%
S&P 5007,041.2818.330.26%
S&P/ASX 2008,946.9036.800.41%
SSE Composite Index4,051.434.12-0.10%

Market Movers